Search

Your search keyword '"Ferrero, Dario"' showing total 250 results
Start Over Author "Ferrero, Dario" Language english
250 results on '"Ferrero, Dario"'

2. Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study

Author

Martella, Federica, Cerrano, Marco, Di Cuonzo, Daniela, Secreto, Carolina, Olivi, Matteo, Apolito, Vincenzo, D’Ardia, Stefano, Frairia, Chiara, Giai, Valentina, Lanzarone, Giuseppe, Urbino, Irene, Freilone, Roberto, Giaccone, Luisa, Busca, Alessandro, Dellacasa, Chiara Maria, Audisio, Ernesta, Ferrero, Dario, and Beggiato, Eloise

Published
2022
Full Text
View/download PDF

5. Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7

Author

Crisà, Elena, Kulasekararaj, Austin G., Adema, Vera, Such, Esperanza, Schanz, Julie, Haase, Detlef, Shirneshan, Katayoon, Best, Steven, Mian, Syed A, Kizilors, Aytug, Cervera, José, Lea, Nicholas, Ferrero, Dario, Germing, Ulrich, Hildebrandt, Barbara, Martínez, Ana Belén Valencia, Santini, Valeria, Sanz, Guillermo F., Solé, Francesc, and Mufti, Ghulam J.

Published
2020
Full Text
View/download PDF

7. Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline

Author

Crugnola, Monica, Castagnetti, Fausto, Breccia, Massimo, Ferrero, Dario, Trawinska, Malgorzata Monika, Abruzzese, Elisabetta, Annunziata, Mario, Stagno, Fabio, Tiribelli, Mario, Binotto, Gianni, Bonifacio, Massimiliano, Fava, Carmen, Iurlo, Alessandra, Bucelli, Cristina, Mansueto, Giovanna, Gozzini, Antonella, Falzetti, Franca, Montefusco, Enrico, Crisà, Elena, Gugliotta, Gabriele, Russo, Sabina, Cedrone, Michele, RussoRossi, Antonella, Pregno, Patrizia, Isidori, Alessandro, Mauro, Endri, Atelda, Romano, Giglio, Gianfranco, Celesti, Francesca, Sorà, Federica, Storti, Sergio, D’Addosio, Adam, Galimberti, Sara, Orlandi, Ester, Calistri, Elisabetta, Bocchia, Monica, Cavazzini, Francesco, Rege Cambrin, Giovanna, Orofino, Nicola, Luciano, Luigiana, Sgherza, Nicola, Rosti, Gianantonio, Latagliata, Roberto, and Capodanno, Isabella

Published
2019
Full Text
View/download PDF

9. Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience

Author

Urbino, Irene, Secreto, Carolina, Apolito, Vincenzo, Olivi, Matteo, Arrigo, Giulia, Boscaro, Eleonora, Catania, Federica Maria, D’Ardia, Stefano, Frairia, Chiara, Giai, Valentina, Freilone, Roberto, Bruno, Benedetto, Lanzarone, Giuseppe, Giaccone, Luisa, Busca, Alessandro, Dellacasa, Chiara Maria, Ferrero, Dario, Audisio, Ernesta, and Cerrano, Marco

Published
2024
Full Text
View/download PDF

10. Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax.

Author

Apolito, Vincenzo, Arrigo, Giulia, Vasseur, Loic, Olivi, Matteo, Perrone, Silvia, Giai, Valentina, Secreto, Carolina, Di Biase, Federica, De Simone, Maria Carla, Copia, Carolina, Gravetti, Angela, Freilone, Roberto, Bruno, Benedetto, Lanzarone, Giuseppe, Beggiato, Eloise, Frairia, Chiara, Audisio, Ernesta, D'Ardia, Stefano, Ferrero, Dario, and Cerrano, Marco

Subjects
ACUTE myeloid leukemia, VENETOCLAX, MORTALITY, OVERALL survival
Abstract

This article discusses the validation of the SIE/SIES/GITMO consensus criteria, also known as the Ferrara criteria, for predicting early mortality and survival in acute myeloid leukemia (AML) patients treated with hypomethylating agents and venetoclax. The study collected data from AML patients who received this treatment and retrospectively applied the Ferrara criteria to evaluate their impact on patient outcomes. The results showed that being unfit for non-intensive chemotherapy was associated with shorter overall survival and increased early mortality in both newly diagnosed and relapsed/refractory patients. The study suggests that the Ferrara criteria can be used to identify AML patients who may not benefit from this treatment. [Extracted from the article]

Published
2023
Full Text
View/download PDF

11. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)

Author

Oliva, Esther Natalie, Riva, Marta, Niscola, Pasquale, Santini, Valeria, Breccia, Massimo, Giai, Valentina, Poloni, Antonella, Patriarca, Andrea, Crisà, Elena, Capodanno, Isabella, Salutari, Prassede, Reda, Gianluigi, Cascavilla, Nicola, Ferrero, Dario, Guarini, Attilio, Tripepi, Giovanni, Iannì, Giuseppe, Russo, Emilio, Castelli, Andrea, Fattizzo, Bruno, Beltrami, Germana, Bocchia, Monica, Molteni, Alfredo, Fenaux, Pierre, Germing, Ulrich, Ricco, Alessandra, Palumbo, Giuseppe A, Impera, Stefana, Di Renzo, Nicola, Rivellini, Flavia, Buccisano, Francesco, Stamatoullas-Bastard, Aspasia, Liberati, Anna Marina, Candoni, Anna, Delfino, Ilaria Maria, Arcadi, Maria Teresa, Cufari, Patrizia, Rizzo, Lorenzo, Bova, Irene, D'Errigo, Maria Grazia, Zini, Gina, and Latagliata, Roberto

Subjects
Settore MED/15
Published
2023

12. Modern Measurements: Fundamentals and Applications

Author

Alessandro Ferrero, Dario Petri, Paolo Carbone, Marcantonio Catelani, Alessandro Ferrero, Dario Petri, Paolo Carbone, Marcantonio Catelani and Alessandro Ferrero, Dario Petri, Paolo Carbone, Marcantonio Catelani, Alessandro Ferrero, Dario Petri, Paolo Carbone, Marcantonio Catelani

Published
2015

13. PB2670: EQOL‐MDS TRIAL: PATIENT‐REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.

Author

Oliva, Esther, Iannì, Giuseppe, Riva, Marta, Niscola, Pasquale, Santini, Valeria, Breccia, Massimo, Gaidano, Valentina, Poloni, Antonella, Patriarca, Andrea, Crisà, Elena, Capodanno, Isabella, Salutari, Prassede, Reda, Gianluigi, Sanpaolo, Grazia, Ferrero, Dario, Guarini, Attilio, Tripepi, Giovanni, Castelli, Andrea, Fattizzo, Bruno, and Beltrami, Germana

Published
2023
Full Text
View/download PDF

14. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

Author

Iurlo, Alessandra, Galimberti, Sara, Abruzzese, Elisabetta, Annunziata, Mario, Bonifacio, Massimiliano, Latagliata, Roberto, Pregno, Patrizia, Ferrero, Dario, Sorà, Federica, Orlandi, Ester Maria, Fava, Carmen, Cattaneo, Daniele, Bucelli, Cristina, Binotto, Gianni, Pungolino, Ester, Tiribelli, Mario, Gozzini, Antonella, Gugliotta, Gabriele, Castagnetti, Fausto, Stagno, Fabio, Rege-Cambrin, Giovanna, Martino, Bruno, Luciano, Luigiana, Breccia, Massimo, Sica, Simona, Bocchia, Monica, Pane, Fabrizio, Saglio, Giuseppe, Rosti, Gianantonio, Specchia, Giorgina, Cortelezzi, Agostino, and Baccarani, Michele

Published
2017
Full Text
View/download PDF

15. Proceedings of the Eighth Italian Conference on Computational Linguistics CliC-it 2021

Author

Achena, Flavia, Aggarwal, Akshay, Albanesi, Davide, Albertin, Giorgia, Alzetta, Chiara, Anselma, Luca, Aparaschivei, Lavinia, Archetti, Francesco, Barattieri di San Pietro, Chiara, Barrón-Cedeño, Alberto, Basile, Pierpaolo, Basile, Valerio, Basili, Roberto, Bellandi, Andrea, Bosco, Cristina, Bosque-Gil, Julia, Brunato, Dominique, Brutti, Alessio, Budeanu, Ancuta, Cabrio, Elena, Canazza, Sergio, Candelieri, Antonio, Caselli, Tommaso, Casola, Silvia, Cassotti, Pierluigi, Cattoni, Roldano, Cecchini, Flavio Massimiliano, Celli, Fabio, Cerulli, Aldo, Cettolo, Mauro, Chesi, Cristiano, Cignarella, Alessandra Teresa, Cimiano, Philipp, Cimino, Andrea, Colella, Annalisa, Croce, Danilo, Cutugno, Francesco, Dall’Acqua, Anna, Dangelo, Paolo, Dei Rossi, Stefano, Dell’Orletta, Felice, Demartini, Silvia, De Gemmis, Marco, De Mattei, Lorenzo, Dini, Irene, Di Bratto, Martina, di Buono, Maria Pia, Di Caro, Luigi, Di Liello, Luca, Di Maro, Maria, Dufaux, Alain, Duzha, Armend, Elahi, Mohammad Fazleh, Ell, Basil, Ernandes, Marco, Fabrizi, Samuel, Fallucchi, Francesca, Fantoli, Margherita, Fernández, Raquel, Ferrari, Pier Luigi, Ferrero, Dario, Ferri, Fabio, Fersini, Elisabetta, Florio, Komal, Flouris, Giorgos, Frenda, Simona, Frey, Jennifer-Carmen, Gattero, Valerio, Gemelli, Sara, Gemmis, Marco de, Giovannetti, Emiliano, Gismondi, Biancamaria, Grasso, Francesca, Grotto, Francesco, Iacono, Maria, Iovine, Andrea, Jansen, Lennert, Jezek, Elisabetta, Kaplan, Frédéric, Labruna, Tiziano, Lai, Mirko, Lavelli, Alberto, Lenci, Alessandro, Litta, Eleonora, Lombardi, Agnese, Lops, Pasquale, Louvan, Samuel, Luzietti, Roberta Bianca, Maffia, Marta, Magnini, Bernardo, Mahed Mousavi, Seyed, Mambrini, Francesco, Marchi, Simone, Marelli, Marco, Marra, Andrea, Martino, Maria De, Marziano, Giuseppe, Masini, Francesca, Mastromattei, Michele, Mattiola, Simone, Mazzei, Alessandro, Messina, Enza, Miaschi, Alessio, Minnema, Gosse, Montemagni, Simonetta, Moretti, Giovanni, Moschitti, Alessandro, Negri, Matteo, Negro, Roberto, Nicolas, Lionel, Nissim, Malvina, Nolano, Gennaro, Ògúnrẹ̀mí, Tolúlọpẹ, Onorati, Dario, Origlia, Antonio, Orrico, Riccardo, Paccosi, Teresa, Palmero Aprosio, Alessio, Papadakos, Panagiotis, Papantoniou, Katerina, Papi, Sara, Papini, Mafalda, Passaro, Lucia C., Passarotti, Marco, Patti, Viviana, Pezzelle, Sandro, Plank, Barbara, Plexousakis, Dimitris, Pretto, Niccolò, Puccinelli, Daniele, Ranaldi, Leonardo, Ravelli, Andrea Amelio, Reverberi, Carlo, Riccardi, Giuseppe, Rocchietti, Guido, Romani, Emma, Rosato, Luca, Rossi, Laura, Roth, Dan, Ruffolo, Paolo, Ruzzetti, Elena Sofia, Sabri, Nazanin, Salaris, Sara, Sanguinetti, Manuela, Schettino, Loredana, Schmalz, Veronica Juliana, Sciolette, Flavia, Semeraro, Giovanni, Siciliani, Lucia, Simi, Maria, Sinclair, Arabella, Sprugnoli, Rachele, Stemle, Egon W., Stranisci, Marco Antonio, Tamburini, Fabio, Terragni, Silvia, Tesei, Andrea, Tonelli, Sara, Tripodi, Rocco, Turchi, Marco, Uryupina, Olga, van der Goot, Margot J., Ventura, Viviana, Venturi, Giulia, Villata, Serena, Vorakitphan, Vorakit, Zanchi, Chiara, Zanzotto, Fabio Massimo, Zeman, Daniel, Zugarini, Andrea, Fersini, Elisabetta, Passarotti, Marco, and Patti, Viviana

Subjects
Computational Linguistics, linguistica, linguistique computationelle, Linguistics, LAN009000, CF, linguistica computazionale, linguistique, Language
Abstract

The eighth edition of the Italian Conference on Computational Linguistics (CLiC-it 2021) was held at Università degli Studi di Milano-Bicocca from 26th to 28th January 2022. After the edition of 2020, which was held in fully virtual mode due to the health emergency related to Covid-19, CLiC-it 2021 represented the first moment for the Italian research community of Computational Linguistics to meet in person after more than one year of full/partial lockdown.

Published
2022

16. Query in linguaggio naturale per il dominio della dieta mediterranea

Author

Anselma, Luca, Ferrero, Dario, and Mazzei, Alessandro

Subjects
Computational Linguistics, linguistica, linguistique computationelle, Linguistics, linguistica computazionale, linguistique, Language
Abstract

This paper presents an ongoing work for allowing users to ask questions in natural language to a database management system on the domain of recipes. The system translates questions from Italian language to SQL exploiting an interlingua represented by a logical formalism such as relational calculus. There are two specific features of this project: first, the use of relational calculus as semantic representation for interlingua translation; second, the role played by pragmatic information, that is the Mediterranean diet domain implicitly encoded in the database schema. Questo articolo presenta un progetto in corso sulla per permettere a degli utenti di porre domande a un database management system nell’ambito del dominio delle ricette. Il sistema traduce le domande da italiano a SQL sfruttando una rappresentazione logica interlingua che consiste nel calcolo relazionale. Ci sono due specifiche caratteristiche di questo progetto: l’uso del calcolo relazionale come rappresentazione semantica della traduzione interlingua e il ruolo giocato dall’informazione pragmatica, che consiste nell’uso del dominio della dieta mediterranea che è stato codificata nello schema del database.

Published
2022

17. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

Author

Breccia, Massimo, Luciano, Luigiana, Latagliata, Roberto, Castagnetti, Fausto, Ferrero, Dario, Cavazzini, Francesco, Trawinska, Malgorzata Monica, Annunziata, Mario, Stagno, Fabio, Tiribelli, Mario, Binotto, Gianni, Crisà, Elena, Musto, Pellegrino, Gozzini, Antonella, Cavalli, Laura, Montefusco, Enrico, Iurlo, Alessandra, Russo, Sabina, Cedrone, Michele, Rossi, Antonella Russo, Pregno, Patrizia, Endri, Mauro, Spadea, Antonio, Molica, Matteo, Giglio, Gianfranco, Celesti, Francesca, Sorà, Federica, Storti, Sergio, D’Addosio, Ada, Cambrin, Giovanna Rege, Isidori, Alessandro, Sica, Simona, Abruzzese, Elisabetta, Speccha, Giorgina, Rosti, Gianantonio, and Alimena, Giuliana

Published
2014
Full Text
View/download PDF

18. Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors.

Author

Boscaro, Eleonora, Urbino, Irene, Catania, Federica Maria, Arrigo, Giulia, Secreto, Carolina, Olivi, Matteo, D'Ardia, Stefano, Frairia, Chiara, Giai, Valentina, Freilone, Roberto, Ferrero, Dario, Audisio, Ernesta, and Cerrano, Marco

Subjects
GENETIC mutation, INDIVIDUALIZED medicine, RNA, RISK assessment, GENOMICS, PREDICTION models
Abstract

Simple Summary: Several factors, both patient- and disease-related, are essential to accurately estimate acute myeloid leukemia (AML) prognosis. The rapidly evolving field, from both the genetic and therapeutic standpoints, and the availability of measurable residual disease (MRD) data have made traditional prognostic factors less reliable. Consequently, updated recommendations are trying to recapitulate the current scenario, but several questions remain to be answered, including the impact of complex co-mutational patterns and the role of clonal architecture. In the present review, we summarize established and new AML risk factors, and we discuss the emerging comprehensive approaches to effectively integrate all relevant prognostic data to better inform patient care. An accurate estimation of AML prognosis is complex since it depends on patient-related factors, AML manifestations at diagnosis, and disease genetics. Furthermore, the depth of response, evaluated using the level of MRD, has been established as a strong prognostic factor in several AML subgroups. In recent years, this rapidly evolving field has made the prognostic evaluation of AML more challenging. Traditional prognostic factors, established in cohorts of patients treated with standard intensive chemotherapy, are becoming less accurate as new effective therapies are emerging. The widespread availability of next-generation sequencing platforms has improved our knowledge of AML biology and, consequently, the recent ELN 2022 recommendations significantly expanded the role of new gene mutations. However, the impact of rare co-mutational patterns remains to be fully disclosed, and large international consortia such as the HARMONY project will hopefully be instrumental to this aim. Moreover, accumulating evidence suggests that clonal architecture plays a significant prognostic role. The integration of clinical, cytogenetic, and molecular factors is essential, but hierarchical methods are reaching their limit. Thus, innovative approaches are being extensively explored, including those based on "knowledge banks". Indeed, more robust prognostic estimations can be obtained by matching each patient's genomic and clinical data with the ones derived from very large cohorts, but further improvements are needed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)

Author

Lanino, Luca, Salutari, Prassede, Perego, Alessandra, Fattizzo, Bruno, Riva, Marta, Ubezio, Marta, Musto, Pellegrino, Cilloni, Daniela, Oliva, Esther Natalie, Voso, Maria Teresa, Pelizzari, Anna Maria, Poloni, Antonella, Capodanno, Isabella, Elena, Chiara, Fozza, Claudio, Pane, Fabrizio, Breccia, Massimo, De Gobbi, Marco, Di Bassiano, Francesco, Barraco, Daniela, Crisà, Elena, Ferrero, Dario, Frairia, Chiara, Vaccarino, Antonella, Griguolo, Davide, Paolini, Stefania, Quintini, Martina, Sessa, Mariarosaria, Turrini, Mauro, Bocchia, Monica, Di Renzo, Nicola, Diral, Elisa, Foli, Cristina, Molteni, Alfredo, Occhini, Ubaldo, Rivoli, Giulia, Selleri, Carmine, Bono, Roberto, Calvisi, Anna, Castelli, Andrea, Di Bona, Eros, Di Veroli, Ambra, Fianchi, Luana, Galimberti, Sara, Grimaldi, Daniele, Marchetti, Monia, Norata, Marianna, Rambaldi, Alessandro, Tanasi, Ilaria, Tosi, Patrizia, Naldi, Ilaria, Santini, Valeria, and Della Porta, Matteo G.

Published
2022
Full Text
View/download PDF

21. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

Author

Gugliotta, Gabriele, Castagnetti, Fausto, Palandri, Francesca, Breccia, Massimo, Intermesoli, Tamara, Capucci, Adele, Martino, Bruno, Pregno, Patrizia, Rupoli, Serena, Ferrero, Dario, Gherlinzoni, Filippo, Montefusco, Enrico, Bocchia, Monica, Tiribelli, Mario, Pierri, Ivana, Grifoni, Federica, Marzocchi, Giulia, Amabile, Marilina, Testoni, Nicoletta, Martinelli, Giovanni, Alimena, Giuliana, Pane, Fabrizio, Saglio, Giuseppe, Baccarani, Michele, and Rosti, Gianantonio

Published
2011
Full Text
View/download PDF

23. Lack of efficacy of convalescent plasma in COVID‐19 patients with concomitant hematological malignancies: An Italian retrospective study.

Author

Lanza, Francesco, Monaco, Federica, Ciceri, Fabio, Cairoli, Roberto, Sacchi, Maria Vittoria, Guidetti, Anna, Marchetti, Monia, Massaia, Massimo, Arcaini, Luca, Krampera, Mauro, Mohamed, Sara, Gherlinzoni, Filippo, Mecucci, Cristina, Gentile, Massimo, Romano, Ilaria, Venditti, Adriano, Ruggeri, Marco, Ferrero, Dario, Coviello, Elisa, and Fabbri, Elisabetta

Subjects
CONVALESCENT plasma, COVID-19, HEMATOLOGIC malignancies, PROPENSITY score matching, INTENSIVE care units
Abstract

A multicenter retrospective study was designed to assess clinical outcome of COVID‐19 in patients with hematological malignancies (HM) following treatment with anti‐SARS‐CoV‐2 convalescent plasma (CP) or standard of care therapy. To this aim, a propensity score matching was used to assess the role of non‐randomized administration of CP in this high‐risk cohort of patients from the Italian Hematology Alliance on COVID‐19 (ITA‐HEMA‐COV) project, now including 2049 untreated control patients. We investigated 30‐ and 90‐day mortality, rate of admission to intensive care unit, proportion of patients requiring mechanical ventilatory support, hospitalization time, and SARS‐CoV‐2 clearance in 79 CP recipients and compared results with 158 propensity score‐matched controls. Results indicated a lack of efficacy of CP in the study group compared with the untreated group, thus confirming the negative results obtained from randomized studies in immunocompetent individuals with COVID‐19. In conclusion, this retrospective analysis did not meet the primary and secondary end points in any category of immunocompromized patients affected by HM. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

28. Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study

Author

Latagliata, Roberto, Ferrero, Dario, Iurlo, Alessandra, Cavazzini, Francesco, Castagnetti, Fausto, Abruzzese, Elisabetta, Fava, Carmen, Breccia, Massimo, Annunziata, Mario, Stagno, Fabio, Tiribelli, Mario, Binotto, Gianni, Mansueto, Giovanna, Gozzini, Antonella, Russo, Sabina, Cavalli, Laura, Montefusco, Enrico, Gugliotta, Gabriele, Cedrone, Michele, Russo Rossi, Antonella, Avanzini, Paolo, Pregno, Patrizia, Mauro, Endri, Spadea, Antonio, Celesti, Francesca, Giglio, Gianfranco, Isidori, Alessandro, Crugnola, Monica, Calistri, Elisabetta, Sorà, Federica, Storti, Stefano, D’Addosio, Ada, Rege-Cambrin, Giovanna, Luciano, Luigiana, and Alimena, Giuliana

Published
2013
Full Text
View/download PDF

29. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

Author

Piva, Roberto, Ruggeri, Bruce, Williams, Michael, Costa, Giulia, Tamagno, Ilaria, Ferrero, Dario, Giai, Valentina, Coscia, Marta, Peola, Silvia, Massaia, Massimo, Pezzoni, Gabriella, Allievi, Cecilia, Pescalli, Nicoletta, Cassin, Mara, di Giovine, Stefano, Nicoli, Paola, de Feudis, Paola, Strepponi, Ivan, Roato, Ilaria, Ferracini, Riccardo, Bussolati, Benedetta, Camussi, Giovanni, Jones-Bolin, Susan, Hunter, Kathryn, Zhao, Hugh, Neri, Antonino, Palumbo, Antonio, Berkers, Celia, Ovaa, Huib, Bernareggi, Alberto, and Inghirami, Giorgio

Published
2008
Full Text
View/download PDF

35. Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes

Author

Falco, Patrizia, Levis, Alessandro, Stacchini, Alessandra, Ciriello, Maria M., Geuna, Massimo, Notari, Patrizia, Omedè, Paola, Pautasso, Marisa, Prato, Giuseppina, Strola, Giuliana, Gioia, Daniela, Bonferroni, Margherita, Cametti, Gianni, Ferrero, Dario, Freilone, Roberto, Gaidano, Gianluca, Marinone, Carlo, Marmont, Filippo, Pollio, Berardino, Salvi, Flavia, Saglio, Giuseppe, and Girotto, Mauro

Published
2011
Full Text
View/download PDF

37. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview

Author

Baccarani, Michele Castagnetti, Fausto Gugliotta, Gabriele and Rosti, Gianantonio Soverini, Simona Albeer, Ali Pfirrmann, Markus Bekadja, Mohamed-Amine Entasoltan, Badra Nachi, Mourad Elghandour, Ashraf El Sorady, Manal Abdelfattah, Raafat El Nahass, Yasser Samra, Mohamed Azzazi, Mohammed and Elsobki, Ezat Moussa, Mohamed Fahmy, Omar Mattar, Mervat and Shehata, Samir Eid Azmy, Emad Bolarinwa, Rahman A. Eid, Samir Khelif, Abderrhaim Hached, Farhat Menif, Samia and Rahman, Hafizur Huang, Xiaojun Jiang, Qian Ye, Yuanxin and Zhu, Huanling Chen, Suning Varma, Neelam Ganesan, Prasanth and Gundeti, Sadashivudu Malhotra, Hemant Radhakrishnan, Vivek S. Kumar, Lalit Sharawat, Surender Kumar Seth, Tulika and Ausekar, B. V. Balasubramanian, Poonkuzhali Poopak, Behzad and Inokuchi, Koiti Kim, Dong-Wook Al Kindi, Salam Mirasol, Angelina Qari, Mohammed Goh, Yeow Tee Shih, Lee-Yung and Branford, Susan Lion, Thomas Valent, Peter Burgstaller, Sonja Thaler, Joseph Labar, Boris Zadro, Renata Mayer, Jiri Zackova, Daniela Faber, Edgar Pallisgaard, Niels and Xavier-Mahon, Francois Lippert, Eric Cayuela, Jean Michel and Rea, Delphine Millot, Frederic Suttorp, Meinolf Hochhaus, Andreas Niederwieser, Dietger Saussele, Susanne Haferlach, Torsten Jeromine, Sabine Panayiotidis, Panayiotis Conneally, Eibhlin Langabeer, Steve Nagler, Arnon Rupoli, Serena and Santoro, Nicola Albano, Francesco Castagnetti, Fausto and Ottaviani, Emanuela Rambaldi, Alessandro Stagno, Fabio and Molica, Stefano Biagiotti, Caterina Scappini, Barbara and Lemoli, Roberto Iurlo, Alessandra Pungolino, Ester Menna, Giuseppe Pane, Fabrizio Gottardi, Enrico Rege-Cambrin, Giovanna Binotto, Gianni Putti, Maria Caterina Falzetti, Franca Visani, Giuseppe Galimberti, Sara Musto, Pellegrino and Abruzzese, Elisabetta Breccia, Massimo Giona, Fiorina and Chiusolo, Patrizia Sica, Simona Fava, Carmen Ferrero, Dario and Tiribelli, Mario Bonifacio, Massimiliano Griskevicius, Laimonas Musteata, Vasile Janssen, Jeroen Prejzner, Witold and Sacha, Tomasz Waclaw, Joanna Almeida, Antonio Medina and Kulikov, Sergei Turkina, Anna Bogdanovic, Andrija Zupan, Irena Marce, Silvia Cervantes, Francisco Steegmann, Juan Luis Kotlyarchuk, Konstyantyn Milner, Benedict J. Rose, Susan Clench, Tim Waits, Paula Austin, Steve Wickham, Caroline Clark, Richard Apperley, Jane Claudiani, Simone and Foroni, Letizia Szydlo, Richard Burt, Emma Bescoby, Ruth and Cork, Leanne O'Brien, Stephen Green, Bethaney Hawtree, Sarah and Watson, Mark Bengio, Raquel Maria Larripa, Irene and Pavlovsky, Carolina Moiraghi, Beatriz Requiao de Pinna, Cristiane Almeida Romani Magalhaes, Gustavo Henrique Pagnano, Katia Funke, Vaneuza Tavares, Renato Sampaio Prado, Adriana and Azevedo, Alita Andrade Fogliatto, Laura Bonecker, Simone and Centrone, Renato Moellman, Artur Conchon, Monika Centurion, Maria Elida Prado, Ana-Ines Lopez, J. L. Petruzziello, Fara and Bendit, Israel Int BCR-ABL Study Grp

Subjects
hemic and lymphatic diseases
Abstract

There are different BCR-ABL1 fusion genes that are translated into proteins that are different from each other, yet all leukemogenic, causing chronic myeloid leukemia (CML) or acute lymphoblastic leukemia. Their frequency has never been systematically investigated. In a series of 45503 newly diagnosed CML patients reported from 45 countries, it was found that the proportion of e13a2 (also known as b2a2) and of e14a2 (also known as b3a2), including the cases co-expressing e14a2 and el 3a2, was 37.9% and 62.1%, respectively. The proportion of these two transcripts was correlated with gender, e13a2 being more frequent in males (39.2%) than in females (36.2%), was correlated with age, decreasing from 39.6% in children and adolescents down to 31.6% in patients >= 80 years old, and was not constant worldwide. Other, rare transcripts were reported in 666/34561 patients (1.93%). The proportion of rare transcripts was associated with gender (2.27% in females and 1.69% in males) and with age (from 1.79% in children and adolescents up to 3.84% in patients >= 80 years old). These data show that the differences in proportion are not by chance. This is important, as the transcript type is a variable that is suspected to be of prognostic importance for response to treatment, outcome of treatment, and rate of treatment-free remission.

Published
2019

39. Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.

Author

Clavio, Marino, Crisà, Elena, Miglino, Maurizio, Guolo, Fabio, Ceccarelli, Manuela, Salvi, Flavia, Allione, Bernardino, Ferrero, Dario, Balleari, Enrico, Finelli, Carlo, Poloni, Antonella, Selleri, Carmine, Danise, Paolo, Cilloni, Daniela, Di Tucci, Anna Angela, Cametti, Gianni, Freilone, Roberto, Fanin, Renato, Bigazzi, Catia, and Zambello, Renato

Subjects
OVERALL survival, MYELODYSPLASTIC syndromes, HEMATOPOIETIC stem cell transplantation, AZACITIDINE, TERMINATION of treatment
Abstract

Background: Azacitidine (AZA) is the standard treatment for myelodysplastic syndromes (MDS); however, many patients prematurely stop therapy and have a dismal outcome.Methods: The authors analyzed outcomes after AZA treatment for 402 MDS patients consecutively enrolled in the Italian MDS Registry of the Fondazione Italiana Sindromi Mielodisplastiche, and they evaluated the North American MDS Consortium scoring system in a clinical practice setting.Results: At treatment discontinuation, 20.3% of the patients were still responding to AZA, 35.4% of the cases had primary resistance, and 44.3% developed adaptive resistance. Overall survival (OS) was better for patients who discontinued treatment while in response because of planned allogeneic hematopoietic stem cell transplantation (HSCT; median OS, not reached) in comparison with patients with primary resistance (median OS, 4 months) or adaptive resistance (median OS, 5 months) or patients responsive but noncompliant/intolerant to AZA (median OS, 4 months; P = .004). After AZA discontinuation, 309 patients (77%) received best supportive care (BSC), 60 (15%) received active treatments, and 33 (8%) received HSCT. HSCT was associated with a significant survival advantage, regardless of the response to AZA. The North American MDS Consortium scoring system was evaluable in 278 of the 402 cases: patients at high risk had worse OS than patients at low risk (3 and 7 months, respectively; P < .001). The score was predictive of survival both in patients receiving BSC (median OS, 2 months for high-risk patients vs 5 months for low-risk patients) and in patients being actively treated (median OS, 8 months for high-risk patients vs 16 months for low-risk patients; P < .001), including transplant patients.Conclusions: Real-life data confirm that this prognostic scoring system for MDS patients failing a hypomethylating agent seems to be a useful tool for optimal prognostic stratification and for choosing a second-line treatment after AZA discontinuation. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

40. PB2057: THE COMBINATION OF ANTI‐COMPLEMENT THERAPY AND CYCLOSPORINE +/‐ ELTROMBOPAG IN PNH IS EFFECTIVE AND SAFE: A REAL‐LIFE OBSERVATIONAL STUDY.

Author

Catania, Federica, Frairia, Chiara, Olivi, Matteo, Festuccia, Moreno, Rapezzi, Davide, Nicolino, Barbara, Arrigo, Giulia, Boscaro, Eleonora, DI Biase, Federica, Cerrano, Marco, Urbino, Irene, Beggiato, Eloise, Lanzarone, Giuseppe, Dellacasa, Chiara Maria, Busca, Alessandro, Ferrero, Dario, D’ardia, Stefano, Audisio, Ernesta, Freilone, Roberto, and Giai, Valentina

Published
2023
Full Text
View/download PDF

43. Immunomodulatory and clinical effects of daratumumab in T‐cell acute lymphoblastic leukaemia.

Author

Cerrano, Marco, Castella, Barbara, Lia, Giuseppe, Olivi, Matteo, Faraci, Danilo G., Butera, Sara, Martella, Federica, Scaldaferri, Matilde, Cattel, Francesco, Boccadoro, Mario, Massaia, Massimo, Ferrero, Dario, Bruno, Benedetto, and Giaccone, Luisa

Subjects
LYMPHOBLASTIC leukemia, ACUTE leukemia, KILLER cells, CYTOTOXIC T cells, VESICLES (Cytology), T cell receptors
Published
2020
Full Text
View/download PDF

44. Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score‐matched analysis.

Author

Balleari, Enrico, Filiberti, Rosa Angela, Salvetti, Chiara, Allione, Bernardino, Angelucci, Emanuele, Bruzzone, Marco, Calzamiglia, Tullio, Cavaliere, Marina, Cavalleri, Maurizio, Cilloni, Daniela, Clavio, Marino, Crisà, Elena, Da Col, Anna, Danise, Paolo, Pilo, Federica, Ferrero, Dario, Finelli, Carlo, Gioia, Daniela, Lemoli, Roberto Massimo, and Masiera, Elisa

Subjects
MYELODYSPLASTIC syndromes, RECOMBINANT erythropoietin, UNIVARIATE analysis, MULTIVARIATE analysis
Abstract

Background: Erythropoiesis‐stimulating agents effectively improve the hemoglobin levels in a fraction of anemic patients with myelodysplastic syndromes (MDS). Higher doses (HD) of recombinant human erythropoietin (rhEPO) have been proposed to overcome suboptimal response rates observed in MDS patients treated with lower "standard doses" (SD) of rhEPO. However, a direct comparison between the different doses of rhEPO is lacking. Methods: A cohort of 104 MDS patients treated with HD was retrospectively compared to 208 patients treated with SD in a propensity score‐matched analysis to evaluate hematological improvement‐erythroid (HI‐E) rate induced by the different doses of rhEPO. The impact of rhEPO doses on survival and progression to leukemia was also investigated. Results: Overall HI‐E rate was 52.6%. No difference was observed between different rhEPO doses (P =.28) in matched cohorts; in a subgroup analysis, transfusion‐dependent patients and patients with higher IPSS‐R score obtained a higher HI‐E rate with HD, although without significant impact on overall survival (OS). Achievement of HI‐E resulted in superior OS. At univariate analysis, a higher HI‐E rate was observed in transfusion‐independent patients (P <.001), with a lower IPSS‐R score (P <.001) and lower serum EPO levels (P =.027). Multivariate analysis confirmed that rhEPO doses were not significantly related to HI‐E (P =.26). There was no significant difference in OS or progression to leukemia in patients treated with HD vs SD. Conclusion: SD are substantially equally effective to HD to improve anemia and influencing survival in MDS patients stratified according to similar propensity to be exposed to rhEPO treatment. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

49. A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

Author

Dragani, Matteo Emidio, Rege Cambrin, Giovanna, Berchialla, Paola, Dogliotti, Irene, Rosti, Gianantonio, Castagnetti, Fausto, Capodanno, Isabella, Cerrano, Marco, Ferrero, Dario, Crugnola, Monica, Elena, Chiara, Breccia, Massimo, Iurlo, Alessandra, Cattaneo, Daniele, Galimberti, Sara, Gozzini, Antonella, Bocchia, Monica, Lunghi, Francesca, Cedrone, Michele, Sgherza, Nicola, Luciano, Luigia, Russo, Sabina, Santoro, Marco, Giai, Valentina, Caocci, Giovanni, Levato, Luciano, Abruzzese, Elisabetta, Sora, Federica, Saglio, Giuseppe, and Fava, Carmen

Published
2019
Full Text
View/download PDF

50. Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Author

Oliva, Esther Natalie, Alati, Caterina, Santini, Valeria, Poloni, Antonella, Riva, Marta, Niscola, Pasquale, Giai, Valentina, Sanpaolo, Grazia, Balleari, Enrico, Crisà, Elena, Ferrero, Dario, Germing, Ulrich, Fenaux, Pierre, Palumbo, Giuseppe A., Salutari, Prassede, Impera, Stefana, Capodanno, Isabella, Reda, Gianluigi, Liberati, Anna Marina, Molteni, Alfredo, Specchia, Giorgina, Buccisano, Francesco, Voso, Maria Teresa, Mancini, Stefano, Bocchia, Monica, Candoni, Anna, Martino, Bruno, Cufari, Patrizia, D'Errigo, Maria Grazia, Zini, Gina, and Latagliata, Roberto

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results